HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.0%

Neg 0% Neu 91% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.